A jihadist gang was inspired by “freely available extremist material” on the internet to plan a bomb attack on a rally of the English Defence League, a judge at the Old Bailey said today. Six men were jailed for up to 19½ years after admitting planning an attack on the far-right group that would have sparked a “tit-for-tat spiral of violence”. Gang members were carrying documents justifying the attack that insulted the Queen as a “kafir [non-believer] female devil” and abused David Cameron. Police discovered that the gang had downloaded from the internet hundreds of terrorist training videos, al-Qaeda manuals and lectures from extremist preachers. Judge Nicholas Hilliard, QC, told the men that they had been inspired by the “tide of apparently freely available extremist material in which most of you had immersed yourselves”. The judge said that the extremist material was “not difficult either to obtain or share”. He said: “In this case, it can only have served to reinforce the defendants’ resolve to behave in the hideous way that was planned.” The attack did not take place because the EDL’s Armed Forces Day rally had ended by the time the gang arrived in Dewsbury, West Yorkshire, in June last year. Judge Hilliard said: “There is no reason to suppose that a further attempt may not have been made in the future had the defendants not been apprehended. I find it inconceivable that your resolve would have evaporat
Am Montag, den 13. März 2005 fand im Northwick Park Hospital in London ein Test mit einem Medikament mit dem Herstellernamen TGN 1412 statt. Es soll zur Behandlung von multipler Sklerose, Blutkrebs und Rheuma eingesetzt werden.

Insgesamt nahmen acht Personen an dem Test teil, zwei davon nahmen Placebos ein. Kurz nach der Einnahme des Medikamentes zeigten sich bei sechs Probanden starke Nebenwirkungen. Zwei Probanden aus dieser Gruppe befinden sich weiterhin in einem kritischen Zustand. Das Pharmaunternehmen TeGenero, in dessen Auftrag das Medikament durch das US-Forschungsunternehmen Parexel International erstmals an Menschen getestet wurde, gibt an, dass es keine Vorfälle bei den vorangehenden Tests an Versuchstieren gegeben haben soll, die auf das Medikament zurückzuführen seien.
 
Die Tests waren für die klinische Entwicklung des neuen Medikaments im Vorfeld des offiziellen Zulassungsverfahrens durchgeführt worden.